Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал:
http://repo.knmu.edu.ua/handle/123456789/23045
Назва: | Kallistatin as a new non-invasive marker in patients with non-alcoholicfattyliver disease combined with hypertension |
Автори: | Rozhdestvenska, Anastasiia Zhelezniakova, Natalia |
Теми: | NAFLD kallistatin hypertension |
Дата публікації: | 2019 |
Бібліографічний опис: | Rozhdestvenska A. Kallistatin as a new non-invasive marker in patients with non-alcoholic fatty liver disease combined with hypertension / A. Rozhdestvenska, N. Zhelezniakova // Current and Emerging Diseases : Maltepe University International Student Congress, Maltepe University, Istanbul, Turkey, 16–17 May 2019. – Istanbul, 2019. – P. 58–59. |
Короткий огляд (реферат): | Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). |
URI (Уніфікований ідентифікатор ресурсу): | https://repo.knmu.edu.ua/handle/123456789/23045 |
Розташовується у зібраннях: | Наукові роботи молодих вчених. Кафедра внутрішньої медицини № 1 |
Файли цього матеріалу:
Файл | Опис | Розмір | Формат | |
---|---|---|---|---|
Rozhdestvenska A. (Kharkiv, Ukraine).docx | 15,78 kB | Microsoft Word XML | Переглянути/відкрити |
Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.